In the news

No Small Plans: Programmable mRNA with Strand Therapeutics

Strand Therapeutics on its Bristol-Myers Squibb LabCentral Golden Ticket Win

BioPharm International

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

Inc.

Messenger RNA Took on Covid-19. This Startup Says That's Just the Beginning

YouTube

Strand Therapeutics targeting solid tumors with with its MIT born technology

Business Wire

Strand Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma

Bloomberg

China's Crackdown on Tech a Headache for Investors (Podcast)

MIT Technology Review

He runs a company that’s figuring out the next steps for messenger RNA

Forbes

This Synthetic Bio Startup Raised $52 Million To Make Tumors Reveal Themselves

Fierce Biotech

Strand snags $52M to develop next-gen mRNA meds for cancer

Endpoints

A pair of former MIT researchers think they've unlocked the next generation of mRNA using synbio 'logic circuits'

CNBC Health and Science

Push for patent waivers is 'political theater' and won't solve vaccine shortage, CEO says

Bloomberg

States Hit by Mad Dash for Gasoline Amid Crisis (Podcast)

Business Insider

Germany is not happy with Biden's support for waiving COVID-19 vaccine patents, predicting severe complications

Business Insider

Global leaders want to override COVID-19 vaccine patents to boost production. It probably isn't going to work.

Bloomberg

Building Vaccines to Counter Future Pandemics (Podcast)

Forbes

Breakthrough Bottlenecks: Deploying Cell Therapies Like 5G And The Case For Biotechnology Infrastructure

Press release

Business Wire

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

April 17, 2023

Business Wire

Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting

March 14, 2023

Business Wire

Strand Therapeutics Appoints Jay Stella as Chief Business Officer

March 1, 2023

Business Wire

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

November 28, 2022

Business Wire

Fierce Biotech names Strand Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

September 12, 2022

Business Wire

Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development

February 08, 2022

Business Wire

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

August 04, 2021

Business Wire

Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35

June 23, 2021

Business Wire

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

June 23, 2021

Business Wire

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

January 11, 2021

Business Wire

Strand Therapeutics Appoints Dr. Dane Wittrup to Scientific Advisory Board and Dr. Mark Frohlich to Newly Formed Clinical Advisory Board

March 11, 2020

Business Wire

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

June 04, 2019

No Small Plans: Programmable mRNA with Strand Therapeutics

Strand Therapeutics on its Bristol-Myers Squibb LabCentral Golden Ticket Win

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

Messenger RNA Took on Covid-19. This Startup Says That's Just the Beginning

Strand Therapeutics targeting solid tumors with with its MIT born technology

Strand Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma

China's Crackdown on Tech a Headache for Investors (Podcast)

He runs a company that’s figuring out the next steps for messenger RNA

This Synthetic Bio Startup Raised $52 Million To Make Tumors Reveal Themselves

Strand snags $52M to develop next-gen mRNA meds for cancer

A pair of former MIT researchers think they've unlocked the next generation of mRNA using synbio 'logic circuits'

Push for patent waivers is 'political theater' and won't solve vaccine shortage, CEO says

States Hit by Mad Dash for Gasoline Amid Crisis (Podcast)

Germany is not happy with Biden's support for waiving COVID-19 vaccine patents, predicting severe complications

Global leaders want to override COVID-19 vaccine patents to boost production. It probably isn't going to work.

Building Vaccines to Counter Future Pandemics (Podcast)

Breakthrough Bottlenecks: Deploying Cell Therapies Like 5G And The Case For Biotechnology Infrastructure

Press release

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting

Strand Therapeutics Appoints Jay Stella as Chief Business Officer

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

Fierce Biotech names Strand Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Strand Therapeutics Appoints Dr. Dane Wittrup to Scientific Advisory Board and Dr. Mark Frohlich to Newly Formed Clinical Advisory Board

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

CONTACT@STRANDTX.COM

237 Putnam Ave
Cambridge, MA 02139 USA

COPYRIGHT 2020
STRAND THERAPEUTICS INC. ALL RIGHTS RESERVED

contact@strandtx.com
‍

Copyright 2020. Designed in California
Strand Therapeutics Inc. All Rights Reserved

No Small Plans: Programmable mRNA with Strand Therapeutics

Strand Therapeutics on its Bristol-Myers Squibb LabCentral Golden Ticket Win

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

Messenger RNA Took on Covid-19. This Startup Says That's Just the Beginning

Strand Therapeutics targeting solid tumors with with its MIT born technology

Strand Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma

China's Crackdown on Tech a Headache for Investors (Podcast)

He runs a company that’s figuring out the next steps for messenger RNA

This Synthetic Bio Startup Raised $52 Million To Make Tumors Reveal Themselves

Strand snags $52M to develop next-gen mRNA meds for cancer

A pair of former MIT researchers think they've unlocked the next generation of mRNA using synbio 'logic circuits'

Push for patent waivers is 'political theater' and won't solve vaccine shortage, CEO says

States Hit by Mad Dash for Gasoline Amid Crisis (Podcast)

Germany is not happy with Biden's support for waiving COVID-19 vaccine patents, predicting severe complications

Global leaders want to override COVID-19 vaccine patents to boost production. It probably isn't going to work.

Building Vaccines to Counter Future Pandemics (Podcast)

Breakthrough Bottlenecks: Deploying Cell Therapies Like 5G And The Case For Biotechnology Infrastructure

Press release

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

Strand Therapeutics Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting

Strand Therapeutics Appoints Jay Stella as Chief Business Officer

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

Fierce Biotech names Strand Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Strand Therapeutics Appoints Dr. Dane Wittrup to Scientific Advisory Board and Dr. Mark Frohlich to Newly Formed Clinical Advisory Board

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

CONTACT@STRANDTX.COM237 Putnam AveCambridge, MA 02139 USA

COPYRIGHT 2020STRAND THERAPEUTICS INC. ALL RIGHTS RESERVED

contact@strandtx.com‍

Copyright 2020. Designed in CaliforniaStrand Therapeutics Inc. All Rights Reserved

CONTACT@STRANDTX.COM

237 Putnam Ave
Cambridge, MA 02139 USA

COPYRIGHT 2020
STRAND THERAPEUTICS INC. ALL RIGHTS RESERVED

contact@strandtx.com
‍

Copyright 2020. Designed in California
Strand Therapeutics Inc. All Rights Reserved